Replimune Group, Inc.
August 04, 2025 - by Joey Ramson
$REPL has managed to gain back some of its losses the past few trading days after shares sank in July on news that the U.S. Food and Drug Administration rejected an application seeking approval of its experimental skin cancer treatment.
